Clinical characteristics and chronic complications in T1D (n=412)
| All patients (n=412) | Glargine U300 (n=187) | Degludec (n=225) | P value | |
| Age (years) | 37.0±13.4 | 37.7±14.1 | 36.6±12.8 | 0.376 |
| Gender male | 214 (52%) | 111 (59.4%) | 103 (45.8%) | 0.004 |
| Diabetes duration (years) | 18.7±12.3 | 17.6±12.6 | 19.8±11.9 | 0.112 |
| Weight (kg) | 72.0±14.9 | 71.7±13.7 | 72.3±15.9 | 0.759 |
| BMI (kg/m2) | 25.3±4.6 | 25.1±4.5 | 25.4±4.8 | 0.551 |
| HbA1c (%) | 7.8±1.4 | 7.6±1.2 | 8.1±1.5 | <0.001 |
| Patients with HbA1c ≤7% | 113 (27.4%) | 65 (35.3%) | 48 (21.5%) | 0.001 |
| Patients with HbA1c ≥8% | 148 (35.9%) | 53 (28.3%) | 95 (42.2%) | 0.003 |
| Carbohydrate counting (%) | 106 (25.7%) | 47 (25.1%) | 59 (26.2%) | 0.458 |
| Patients with FSL (%) | 80 (19.0%) | 27 (14.4%) | 44 (19.6%) | 0.107 |
| Time in range 70–180 mg/dL (%) | 47.3±18.0 | 51.1±14.6 | 45.0±19.5 | 0.183 |
| Time in hypoglycemia <70 mg/dL (%) | 6.8±6.6 | 9.2±8.3 | 5.8±4.4 | 0.053 |
| Time in hyperglycemia >180 mg/dL (%) | 46.5±19.9 | 39.6±16.4 | 50.5±20.7 | 0.023 |
| Active smoking (%) | 101 (24.5%) | 44 (23.5%) | 57 (25.3%) | 0.379 |
| Antihypertensive treatment (%) | 78 (18.9%) | 33 (17.6%) | 45 (20.0%) | 0.307 |
| Lipid-lowering treatment (%) | 147 (35.7%) | 65 (34.7%) | 82 (36.4%) | 0.349 |
| Diabetic retinopathy (%) | 194 (47.0%) | 79 (42.2%) | 115 (51.1%) | 0.056 |
| DR mild-to-moderate | 114 (27.6%) | 43 (23.0%) | 71 (31.5%) | |
| Laser therapy | 53 (12.9%) | 29 (15.5%) | 24 (10.6%) | |
| Surgery | 27 (6.6%) | 7 (3.6%) | 20 (8.9%) | |
| Diabetic nephropathy | 52 (12.6%) | 20 (10.7%) | 32 (14.2%) | 0.327 |
| Albuminuria | 42 (10.2%) | 16 (8.6%) | 26 (11.6%) | |
| Dialysis of kidney transplant | 10 (2.4%) | 4 (2.1%) | 6 (2.7%) | |
| Macrovascular complications (%) | 23 (5.6%) | 9 (4.8%) | 14 (6.2%) | 0.089 |
BMI, body mass index; DR, diabetic retinopathy; FSL, freestyle libre; HbA1c, glycosylated hemoglobin; T1D, type 1 diabetes.